Functional importance of GLP-1 receptor species and expression levels in cell lines

Regulatory Peptides

Volumn 175, Issue 1-3, 2012, Pages 21-29

  Knudsen, Lotte Bjerre ^a   Hastrup, Sven ^a   Underwood, Christina Rye ^a   Wulff, Birgitte Schjellerup ^a   Fleckner, Jan ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

GPCR; Incretin; Liraglutide; Metabolite

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [9-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 [9-37]; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL STRAIN BHK; CHIMPANZEE; CONTROLLED STUDY; HAPLORHINI; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; LIGAND BINDING; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RABBIT; RAT; SIGNAL NOISE RATIO; SPECIES DIFFERENCE; SWINE;

ADENYLATE CYCLASE; AMINO ACID SEQUENCE; ANIMALS; CELL LINE; CELL MEMBRANE; CRICETINAE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; IMMUNOBLOTTING; LUNG; MICE; MOLECULAR SEQUENCE DATA; RABBITS; RATS; RECEPTORS, GLUCAGON; SEQUENCE HOMOLOGY, AMINO ACID; SWINE;

MACACA FASCICULARIS; MAMMALIA; ORYCTOLAGUS CUNICULUS; RATTUS; SUIDAE;

EID: 84858334628     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2011.12.006     Document Type: Article

References (60)

1. Holst J.J. Glucagon-like peptide-1: from extract to agent. The Claude Bernard lecture, 2005. Diabetologia 2006, 49(2):253-260.
2. Drucker D.J., Sherman S.I., Gorelick F.S., Bergenstal R.M., Sherwin R.S., Buse J.B. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 2010, 33(2):428-433.
3. Drucker D.J., Dritselis A., Kirkpatrick P. Liraglutide. Nat Rev Drug Discov 2010, 9(4):267-268.
4. Drucker D.J., Sherman S.I., Bergenstal R.M., Buse J.B. The safety of incretin-based therapies: review of the scientific evidence. J Clin Endocrinol Metab 2011, 96(7):2027-2031.
5. Mojsov S., Weir G.C., Habener J.F. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 1987, 79(2):616-619.
6. Holst J.J., Orskov C., Nielsen O.V., Schwartz T.W. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett 1987, 211(2):169-174.
7. Drucker D.J., Philippe J., Mojsov S., Chick W.L., Habener J.F. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A 1987, 84(10):3434-3438.
8. Pratley R.E., Nauck M., Bailey T., Montanya E., Cuddihy R., Filetti S., et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010, 375(9724):1447-1456.
9. Wang Y.H., Perfetti R., Greig N.H., Holloway H.W., Deore K.A., Montroserafizadeh C., et al. Glucagon-like peptide-1 can reverse the age-related decline in glucose-tolerance in rats. J Clin Invest 1997, 99(12):2883-2889.
10. Sturis J., Gotfredsen C.F., Romer J., Rolin B., Ribel U., Brand C.L., et al. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol 2003, 140(1):123-132.
11. Xu G., Stoffers D.A., Habener J.F., Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999, 48(12):2270-2276.
12. Edvell A., Lindstrom P. Initiation of increased pancreatic islet growth in young normoglycemic mice (Umeå +/?). Endocrinology 1999, 140(2):778-783.
13. Farilla L., Hui H., Bertolotto C., Kang E., Bulotta A., Di M.U., Perfetti R. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002, 143(11):4397-4408.
14. Orskov C., Holst J.J., Nielsen O.V. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 1988, 123(4):2009-2013.
15. Hare K.J., Vilsboll T., Asmar M., Deacon C.F., Knop F.K., Holst J.J. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes 2010, 59(7):1765-1770.
16. Flint A., Raben A., Astrup A., Holst J.J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998, 101(3):515-520.
17. Raun K., von Voss P., Knudsen L.B. Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs. Obesity 2007, 15(7):1710-1716.
18. Holst J.J. The physiology of glucagon-like peptide 1. Physiol Rev 2007, 87(4):1409-1439.
19. 2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995, 44(9):1126-1131.
20. DeFronzo R.A., Ratner R.E., Han J., Kim D.D., Fineman M.S., Baron A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28(5):1092-1100.
21. Buse J.B., Rosenstock J., Sesti G., Schmidt W.E., Montanya E., Brett J.H., et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009, 374(9683):39-47.
22. Knudsen L.B., Nielsen P.F., Huusfeldt P.O., Johansen N.L., Madsen K., Pedersen F.Z., et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000, 43(9):1664-1669.
23. Agerso H., Jensen L.B., Elbrond B., Rolan P., Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002, 45(2):195-202.
24. Fields A.V., Patterson B., Karnik A.A., Shannon R.P. Glucagon-like peptide-1 and myocardial protection: more than glycemic control. Clin Cardiol 2009, 32(5):236-243.
25. Noyan-Ashraf M.H., Abdul M.M., Ban K., Sadi A.M., Zhou Y.Q., Riazi A.M., et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009, 58(4):975-983.
26. Liu H., Dear A.E., Knudsen L.B., Simpson R.W. A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J Endocrinol 2009, 201(1):59-66.
27. Tang-Christensen M., Larsen P.J., Goke R., Fink-Jensen A., Jessop D.S., Moller M., Sheikh S.P. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 1996, 271(4 Pt 2):R848-R856.
28. Gutzwiller J.P., Tschopp S., Bock A., Zehnder C.E., Huber A.R., Kreyenbuehl M., et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004, 89(6):3055-3061.
29. During M.J., Cao L., Zuzga D.S., Francis J.S., Fitzsimons H.L., Jiao X., et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003, 9(9):1173-1179.
30. Martin B., Golden E., Carlson O.D., Pistell P., Zhou J., Kim W., et al. Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease. Diabetes 2009, 58(2):318-328.
31. Bertilsson G., Patrone C., Zachrisson O., Andersson A., Dannaeus K., Heidrich J., et al. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J Neurosci Res 2008, 86(2):326-338.
32. Irwin D.M. Molecular evolution of mammalian incretin hormone genes. Regul Pept 2009, 155(1-3):121-130.
33. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci U S A 1992, 89(18):8641-8645.
34. Thorens B., Porret A., Buhler L., Deng S.P., Morel P., Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 1993, 42(11):1678-1682.
35. Scrocchi L.A., Brown T.J., MacLusky N., Brubaker P.L., Auerbach A.B., Joyner A.L., Drucker D.J. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 1996, 2(11):1254-1258.
36. Kieffer T.J., Habener J.F. The glucagon-like peptides. Endocr Rev 1999, 20(6):876-913.
37. Doyle M.E., Egan J.M. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 2007, 113(3):546-593.
38. Liu Z., Habener J.F. Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation. J Biol Chem 2008, 283(13):8723-8735.
39. Sonoda N., Imamura T., Yoshizaki T., Babendure J.L., Lu J.C., Olefsky J.M. Beta-arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic beta cells. Proc Natl Acad Sci U S A 2008, 105(18):6614-6619.
40. Dozier K.C., Cureton E.L., Kwan R.O., Curran B., Sadjadi J., Victorino G.P. Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation. Peptides 2009, 30(9):1735-1741.
41. Biswas S.C., Buteau J., Greene L.A. Glucagon-like peptide-1 (GLP-1) diminishes neuronal degeneration and death caused by NGF deprivation by suppressing Bim induction. Neurochem Res 2008, 33(9):1845-1851.
42. Knudsen L.B., Madsen L.W., Andersen S., Almholt K., De Boer A.S., Drucker D.J., et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010, 151(4):1473-1486.
43. Adelhorst K., Hedegaard B.B., Knudsen L.B., Kirk O. Structure-activity studies of glucagon-like peptide-1. J Biol Chem 1994, 269(9):6275-6278.
44. Knudsen L.B., Kiel D., Teng M., Behrens C., Bhumralkar D., Kodra J.T., et al. Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc Natl Acad Sci U S A 2007, 104(3):937-942.
45. Nauck M.A., Heimesaat M.M., Orskov C., Holst J.J., Ebert R., Creutzfeldt W. Preserved incretin activity of glucagon-like peptide-1 [7-36 amide] but not of synthetic human gastric-inhibitory polypeptide in patients with type-2 diabetes-mellitus. J Clin Invest 1993, 91(1):301-307.
46. Hojberg P.V., ll T., Rabol R., Knop F.K., Bache M., Krarup T., et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 2009, 52(2):199-207.
47. Ribel U., Larsen M.O., Rolin B., Carr R.D., Wilken M., Sturis J., et al. NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs. Eur J Pharmacol 2002, 451(2):217-225.
48. Scott K.A., Moran T.H. The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size. Am J Physiol Regul Integr Comp Physiol 2007, 293(3):R983-R987.
49. Parthier C., Reedtz-Runge S., Rudolph R., Stubbs M.T. Passing the baton in class B GPCRs: peptide hormone activation via helix induction?. Trends Biochem Sci 2009, 34(6):303-310.
50. Runge S., Thogersen H., Madsen K., Lau J., Rudolph R. Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain. J Biol Chem 2008, 283(17):11340-11347.
51. Runge S., Wulff B.S., Madsen K., Brauner-Osborne H., Knudsen L.B. Different domains of the glucagon and glucagon-like peptide-1 receptors provide the critical determinants of ligand selectivity. Br J Pharmacol 2003, 138(5):787-794.
52. Wilmen A., Eyll B.V., Goke B., Goke R. Five out of six tryptophan residues in the N-terminal extracellular domain of the rat GLP-1 receptor are essential for its ability to bind GLP-1. Peptides 1997, 18(2):301-305.
53. Koole C., Wootten D., Simms J., Valant C., Miller L.J., Christopoulos A., et al. Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function: allosteric rescue of loss of function mutation. Mol Pharmacol 2011, 80(3):486-497.
54. Zhu B.T. The competitive and noncompetitive antagonism of receptor-mediated drug actions in the presence of spare receptors. J Pharmacol Toxicol Methods 1993, 29(2):85-91.
55. Montrose-Rafizadeh C., Avdonin P., Garant M.J., Rodgers B.D., Kole S., Yang H., et al. Pancreatic glucagon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in Chinese hamster ovary cells. Endocrinology 1999, 140(3):1132-1140.
56. Widmann C., Burki E., Dolci W., Thorens B. Signal transduction by the cloned glucagon-like peptide-1 receptor: comparison with signaling by the endogenous receptors of beta cell lines. Mol Pharmacol 1994, 45(5):1029-1035.
57. Schmidtler J., Dehne K., Allescher H.D., Schusdziarra V., Classen M., Holst J.J., et al. Rat parietal cell receptors for GLP-1-(7-36) amide: northern blot, cross-linking, and radioligand binding. Am J Physiol 1994, 267(3 Pt 1):G423-G432.
58. Chen D., Liao J., Li N., Zhou C., Liu Q., Wang G., et al. A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice. Proc Natl Acad Sci U S A 2007, 104(3):943-948.
59. Knudsen L.B., Pridal L. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 1996, 318(2-3):429-435.
60. Ban K., Noyan-Ashraf M.H., Hoefer J., Bolz S.S., Drucker D.J., Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117(18):2340-2350.